SR9009 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-11-15. Numbers and descriptions here follow the published literature rather than marketing material.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Standard peptides synthesized from amino acids labeled with stable isotope atoms serve as internal standards for serial dilutions of a sample. These allow for later absolute quantification of proteins and post-translational modifications by mass spectrometry. This technique has been adapted to absolute quantification of proteases, deciphering both activity states and total amounts in biological samples. This is thanks to trypsin treatment for mass spectrometry generating peptides specific to inactive zymogen precursors, active proteases, or common to both forms. PSPs is one form of standard peptide for absolute quantification and Standard of the Expressed Protease (STEP) is the other. The major difference between the two is PSP sequences are designed to mimic tryptic peptides that contain sequences spanning the zymogen's pro-domain and the protease's final form, whereas STEP sequences match tryptic peptide sequences found in both forms of the protease. This capitalizes on protease activation, where the zymogen's pro-domain is cleaved off and the final form lacks that domain. Experiments using iTRAQ labeling and LC-MS/MS with STEP and PSP peptide internal standards have successfully quantified total and active protease levels in biological samples. One major drawback for this approach is the inability to account for inhibitor bound enzymes. It is also difficult to ensure standard peptides can be generated for this method for each and every protease for study.
== History == Nuclear fusion is normally understood to occur at temperatures in the tens of millions of degrees. This is called "thermonuclear fusion". Since the 1920s, there has been speculation that nuclear fusion might be possible at much lower temperatures by catalytically fusing hydrogen absorbed in a metal catalyst. In 1989, a claim by Stanley Pons and Martin Fleischmann (then one of the world's leading electrochemists) that such cold fusion had been observed caused a brief media sensation before the majority of scientists criticized their claim as incorrect after many found they could not replicate the excess heat. Since the initial announcement, cold fusion research has continued by a small community of researchers who believe that such reactions happen and hope to gain wider recognition for their experimental evidence.
The primary operational ration used by the Hellenic Armed Forces is the Merida Eidikon Dynameon (Special Forces' Ration, also known as a 4B-ration), a 24-hour ration pack inside a cardboard box measuring 240 mm × 140 mm × 130 mm (9.4 in × 5.5 in × 5.1 in) and weighing 1 kg (2.2 lb). Most items are commercially procured, with the main meals in round pull-ring cans. Typical contents include: a 200 g canned meat ("SPAM"); 280 g can of meat with vegetables (beef and potatoes, etc.) (termed Prepared Food With Meat or ΠΦΜΚ); a 280 g can of cooked vegetables (green peas, etc.) (Prepared Food Without Meat or ΠΦΑΚ); an 85 g can of cheese; 6 hard biscuits; 40 g honey; three 50 g packages of raisins or chocolate; 30 g sugar; 1.5 g black tea, 2 g instant coffee; 19 g instant milk powder; two small packets of salt; a multivitamin tablet; 4 water purification tablets; a pack of tissues; a disposable ration heater with 5 fuel tablets; and a box of matches. In wartime, packs of locally commandeered cigarettes may also be issued.
Sources: en.wikipedia.org
Burroughs and others claimed that it was a "metabolic regulator" with a restorative dimension to a damaged or dysfunctional dopaminergic system. Despite anecdotal evidence that this offers a plausible route to an abstinence-based mode, no clinical trials have ever tested this hypothesis. A recent study indicates that apomorphine might be a suitable marker for assessing central dopamine system alterations associated with chronic heroin consumption. There is, however, no clinical evidence that apomorphine is an effective and safe treatment regimen for opiate addiction.
=== Transcriptional activities === The shorter p110 CUX1 isoform stably interacts with DNA and can function as transcriptional repressor or activator depending on promoter context. Transcription and cell-based assays demonstrated a role for p110 CUX1 in stimulating cell cycle progression and cell proliferation, strengthening of the spindle assembly checkpoint, ensuring an efficient DNA damage response, promoting cell migration and invasion, and increasing resistance to apoptotic signals. Of note, the p200 CUX1 protein was inactive in all these transcriptional and cell-based assays. p110 CUX1 has been demonstrated to bind the protective allele of FTO single nucleotide polymorphisms (SNPs) rs8050136 or rs1421085 highly associated with human obesity, and promote the expression of RPGRIP1L. RPGRIP1L hypomorphism in mice results in obesity, suggesting an important role of CUX1 in body weight regulation.
=== Vitamin B12 structure === In 1948, Hodgkin first encountered vitamin B12, one of the most structurally complex vitamins known, and created new crystals. Vitamin B12 had first been discovered at Merck earlier that year. It had a structure at the time that was almost completely unknown, and when Hodgkin discovered it contained cobalt, she realized the structure actualization could be determined by X-ray crystallography analysis. The large size of the molecule, and the fact that the atoms were largely unaccounted for—aside from cobalt—posed a challenge in structure analysis that had not been previously explored. From these crystals, she deduced the presence of a ring structure because the crystals were pleochroic, a finding which she later confirmed using X-ray crystallography. The B12 study published by Hodgkin was described by Lawrence Bragg as being as significant "as breaking the sound barrier". Scientists from Merck had previously crystallised B12, but had published only refractive indices of the substance. The final structure of B12, for which Hodgkin was later awarded the Nobel Prize, was published in 1955 and 1956.
On 29 July, two days after the riot officially ended, 82nd Captain Randolph Smith fatally shot Ernest Roquemore, a 19-year-old black man carrying a transistor radio. Three other individuals were injured by shotgun fire from police in the same incident. The Army and Detroit Police were on a joint patrol to recover looted items within the vicinity. On 30 July, the 82nd and the 101st completely left Detroit and moved back to Selfridge for redeployment to their home stations, a process that continued gradually until 2 August.
Sources: en.wikipedia.org
THC and its 11-OH-THC and THC-COOH metabolites can be detected and quantified in blood, urine, hair, oral fluid or sweat using a combination of immunoassay and chromatographic techniques as part of a drug use testing program or in a forensic investigation. There is ongoing research to create devices capable of detecting THC in breath.
The peptide sequence tag approach developed at the EMBL was one of the first methods for the identification of peptides based on mass spectra and genome data. Nano-electrospray (an electrospray technique with very low flow rates) was the first method that allowed femtomole sequencing of proteins from polyacrylamide gels. A recently developed metabolic labeling technique called SILAC (stable isotope labeling with amino acids in cell culture) is widely used in quantitative proteomics.
=== Pharmacodynamics === Romergoline shows high affinity for the dopamine D2 receptor (Ki = 6.5 nM), α2-adrenergic receptor (Ki = 4.0 nM), and serotonin 5-HT1A receptor (Ki = 4.0 nM). It also possesses moderate (submicromolar) affinity for the dopamine D1 receptor (Ki = 55 nM) and ketanserin-labeled serotonin 5-HT2 receptor (Ki = 24 nM). Conversely, the drug shows slight or negligible affinity for the α1-adrenergic receptor (Ki = 113 nM), muscarinic acetylcholine receptors (Ki = >10,000 nM), and sigma receptors (Ki = >10,000 nM). Romergoline is said to act as both a dopamine receptor agonist and antagonist, depending on the circumstances. More specifically, the drug is said to act as a D2 receptor silent antagonist under normal dopamine-replete circumstances, but in a dopamine-depleted state, it acts as a powerful dopamine D1 receptor full agonist. This transformation of the drug's activity is thought to be due to development of dopamine D1 receptor supersensitivity with dopamine depletion. Romergoline produces hypolocomotion in rodents and monkeys, inhibits apomorphine-induced climbing behavior in rodents, causes antiemetic effects in dogs, strongly increases prolactin levels in rodents, and antagonizes amphetamine-induced toxicity in rodents. With dopamine depletion however, romergoline induces hyperlocomotion and contralateral turning behavior in 6-hydroxydopamine-lesioned rodents, reverses MPTP-induced akinesia and parkinsonism in monkeys, and reverses reserpine-induced hypokinesia.
=== Spider and other silks === Spider silk, particularly the dragline silk of orb-weaving spiders, is both very strong and highly extensible, which places it among the toughest natural fibres known. The principal constraint is supply. Spiders are territorial and cannibalistic and cannot be farmed as silkworms are, so natural spider silk remains scarce. Instead, spider-silk proteins are produced by genetic engineering and expressed in bacteria, yeast or other hosts. Silks from wild silkmoths such as Antheraea species, and from other insects, have also been examined; they differ in amino acid sequence and in how they interact with cells.
==== Output ==== After an incident particle has fused with a parent nucleus, if the excitation energy is sufficient, the nucleus breaks into fragments. This is called scission, and occurs at about 10−20 seconds. The fragments can emit prompt neutrons at between 10−18 and 10−15 seconds. At about 10−11 seconds, the fragments can emit gamma rays. At 10−3 seconds β decay, β-delayed neutrons, and gamma rays are emitted from the decay products. Typical fission events release about two hundred million eV (200 MeV) of energy for each fission event. The exact isotope which is fissioned, and whether or not it is fissionable or fissile, has only a small impact on the amount of energy released. This can be easily seen by examining the curve of binding energy (image below), and noting that the average binding energy of the actinide nuclides beginning with uranium is around 7.6 MeV per nucleon. Looking further left on the curve of binding energy, where the fission products cluster, it is easily observed that the binding energy of the fission products tends to center around 8.5 MeV per nucleon. Thus, in any fission event of an isotope in the actinide mass range, roughly 0.9 MeV are released per nucleon of the starting element. The fission of 235U by a slow neutron yields nearly identical energy to the fission of 238U by a fast neutron. This energy release profile holds for thorium and the various minor actinides as well.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.